← Back to Clinical Trials
Recruiting NCT06857448

NCT06857448 Autologous Point-of-Care Adipose Therapy: Recent Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06857448
Status Recruiting
Phase
Sponsor University of Pittsburgh
Condition Burns
Study Type INTERVENTIONAL
Enrollment 68 participants
Start Date 2025-11-04
Primary Completion 2028-01-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Split Thickness Skin Graft (STSG)Base of wound fat graft with STSG Reconstruction (Autologous Layered Composite Grafting).

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 68 participants in total. It began in 2025-11-04 with a primary completion date of 2028-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to explore if an adipose-based therapeutic strategy can treat full-thickness soft-tissue trauma wounds in injured individuals, especially those with severe burns or soft-tissue loss. The main question it aims to answer are: \- Can immediate autologous adipose and autologous layered composite grafting be effective for acute functional soft-tissue reconstruction? Researchers will compare the single-stage autologous layered composite grafting method to traditional methods to see if it improves healing outcomes, minimizes scarring, and reduces infection risk. Participants will: * Receive immediate fat grafting into the wound. * Undergo simultaneous split-thickness skin grafting for full soft-tissue reconstruction.

Eligibility Criteria

Inclusion Criteria: * The proposed study will include adult patients 18 years of age or older, * male or female, * civilian, military, active duty or retired veterans * presenting for unilateral or bilateral fasciotomy of the extremity at any level necessary * secondary to non-infectious etiology, * unilateral or bilateral traumatic full-thickness skin loss of the face, head, neck or extremities necessitating reconstruction, and/or * full or partial thickness burn injury of the face, neck, or extremity requiring excision and/or reconstruction. * Additional inclusion criteria includes willingness to be randomized to receive a fat graft. Exclusion Criteria: * Age \< 18 years of age, * active infection, * medical co-morbidities or anatomic configuration deemed by the physician to be a concern for safety, * unwilling or unable to comply with study procedures, * radiation to the site of interest, * prisoners and/or vulnerable populations. * In addition, candidates that are pregnant or plan to become pregnant in the next year, will be excluded.

Contact & Investigator

Central Contact

Eleanor Shirley

✉ shirleye@upmc.edu

📞 412-641-8676

Principal Investigator

Francesco Egro

PRINCIPAL INVESTIGATOR

University of Pittsburgh

Frequently Asked Questions

Who can join the NCT06857448 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Burns. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06857448 currently recruiting?

Yes, NCT06857448 is actively recruiting participants. Contact the research team at shirleye@upmc.edu for enrollment information.

Where is the NCT06857448 trial being conducted?

This trial is being conducted at Pittsburgh, United States, Pittsburgh, United States.

Who is sponsoring the NCT06857448 clinical trial?

NCT06857448 is sponsored by University of Pittsburgh. The principal investigator is Francesco Egro at University of Pittsburgh. The trial plans to enroll 68 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology